Background People with cancer are known to be at increased risk of venous
thromboembolism (VTE), and this risk is believed to vary according to cancer type, stage of …

BACKGROUND: Accurate population-based data are needed on the incidence of venous
thromboembolism (VTE) in patients with different cancers in order to inform guidelines on …

The incidence of venous thromboembolism (VTE) in cancer patients may have changed in
the past decade, possibly due to novel cancer therapies, improved survival, and high …

Background: Venous thromboembolism (VTE) frequently complicates cancer. Data on
tumour-specific VTE predictors are limited, but may inform strategies to prevent thrombosis …

Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in patients
with cancer. The risk of VTE varies over the natural history of cancer, with the highest risk …

Cancer is associated with a fourfold increased risk of venous thromboembolism (VTE). The
risk of VTE varies according to the type of malignancy (ie pancreatic cancer, brain cancer …

Venous thromboembolism (VTE) represents a major challenge in the management of
patients with cancer. The malignant phenotype is associated with derangements in the …

The association between cancer and thrombosis has been recognized for more than 150
years. Not only are patients with cancer at a substantially increased risk of developing …

Background Independent risk factors for cancer-associated incident venous
thromboembolism (VTE) and their magnitude of risk are not fully characterized. Aim To …

Purpose Patients with cancer are increasingly at risk for venous thromboembolism (VTE).
Rates of VTE, however, vary markedly among patients with cancer. Design This review …